Parkinson’s disease is a neurodegenerative disorder that primarily affects movement control, leading to symptoms such as tremors, stiffness, bradykinesia (slowness of movement), and postural instability. It affects over 10 million people worldwide, including more than 1 million in North America. The Parkinson’s drug market is valued at over $6 billion, with substantial growth expected. Current treatments include levodopa and dopamine agonists, which help manage symptoms but cannot stop disease progression. There is significant potential for drug development in this area, as the market is expanding with a growing aging population and the need for more effective treatments that target the underlying causes of the disease.
Zebrafish Model: Using MPP+ model to identify potential drugs in 5 dpf larvae